A swimmer plot for patients treated with teclistamab or talquetamab, colored by treatment response according to International Myeloma Working Group response criteria, prior to prolonged dose-delay event(s) and after reinitiation of bispecific antibody therapy. CR, complete response; LDH, lactate dehydrogenase; NE, not evaluable; PD, progressive disease; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.